JAMA Network
About The Study: In people with type 2 diabetes, both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) were statistically significantly associated with decreased risk of Alzheimer disease and related dementias compared with other glucose-lowering drugs, and no difference was observed between both drugs.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
